NCT07100067View on ClinicalTrials.gov

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

NANot yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

February 20, 2028

Study Completion Date

November 20, 2029

Conditions
Relapsed/Refractory Multiple Myeloma(MM)
Interventions
BIOLOGICAL

LCAR- F33S cells intravenous infusion

Prior to infusion of the LCAR- F33S cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.

Trial Locations (4)

Unknown

Beijing Boren Hospital, Beijing

Institute of Hematology & Blood Diseases Hospital, Tianjin

Institute of Hematology & Blood Diseases Hospital, Tianjin

Wuhan Union Hospital, Wuhan

Sponsors
All Listed Sponsors
collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

lead

Nanjing Legend Biotech Co.

INDUSTRY